Hypertension Journal

Register      Login

VOLUME 2 , ISSUE 2 ( April-June, 2016 ) > List of Articles

RESEARCH ARTICLE

Sodium Glucose Cotransporter-2 Inhibitors in Clinical Practice: Impact beyond Glycemic Control

N Karthik Rao, KM Prasanna Kumar

Citation Information : Karthik Rao N, Kumar KP. Sodium Glucose Cotransporter-2 Inhibitors in Clinical Practice: Impact beyond Glycemic Control. Hypertens J 2016; 2 (2):74-79.

DOI: 10.5005/jp-journals-10043-0035

Published Online: 00-06-2016

Copyright Statement:  Copyright © 2016; Jaypee Brothers Medical Publishers (P) Ltd.


Abstract

How to cite this article

Rao NK, Kumar KMP. Sodium Glucose Cotransporter-2 Inhibitors in Clinical Practice: Impact beyond Glycemic Control. Hypertens J 2016;2(2):74-79.


PDF Share
  1. Dapagliflozin: a sodium glucose cotransporter 2 inhibitor in development for type 2 diabetes. Diabetes Ther 2010 Dec;1(2):45-56.
  2. Sodium glucose cotransporter 2 inhibitors as a new treatment for diabetes mellitus. J Clin Endocrinol Metab 2010 Jan;95(1):34-42.
  3. Distinguishing among incretin-based therapies. Pathophysiology of type 2 diabetes mellitus: potential role of incretin-based therapies. J Fam Pract 2010 Sep;59(9 Suppl 1):S5-S9.
  4. Epidemiology of type 2 diabetes: Indian scenario. Indian J Med Res 2007 Mar;125(3):217-230.
  5. Burden of type 2 diabetes and its complications –the Indian scenario. Curr Sci 2002;83:1471-1476.
  6. Chronic complications in newly diagnosed patients with type 2 diabetes mellitus in India. Indian J Endocrinol Metab 2014 May-Jun;18(3):355-360.
  7. Diabetes in South Asians: is the phenotype different? Diabetes 2014 Jan;63(1):53-55.
  8. Canagliflozin provides durable glycemic improvements and body weight reduction over 104 weeks vs glimepiride in patients with type 2 diabetes on metformin: a randomized, double-blind, phase 3 study. Diabetes Care 2015 Mar;38(3):355-364.
  9. Long-term efficacy and safety of canagliflozin over 104 weeks in patients aged 55 to 80 years with type 2 diabetes. Diabetes Obes Metab 2015 Mar;17(3):294-303.
  10. Sodium-glucose co-transport inhibitors: progress and therapeutic potential in type 2 diabetes mellitus. Drugs 2010 Mar 5;70(4):377-385.
  11. Effects of dapagliflozin on body weight, total fat mass and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. J Clin Endocrinol Metab 2012 Mar;97(3):1020-1031.
  12. Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus from India. Diabetes Res Clin Prac 2014 Nov;106:S260-S261.
  13. Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase III trial. Diabetes Care 2010 Oct;33(10):2217-2224.
  14. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial. Diabetes Obes Metab 2011 Oct;13(10):928-938.
  15. Dapagliflozin added-on to pioglitazone reduces HbA1c and mitigates weight gain with low incidence of hypoglycemia in type 2 diabetes [abstract]. Diabetes 2011;60:A270:986-P.
  16. Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial. Ann Intern Med 2012 Mar 20;156(6):405-415.
  17. Type 2 diabetes in East Asians: similarities and differences with populations in Europe and the United States. Ann N Y Acad Sci 2013 Apr;1281(1):64-91.
  18. Adiposopathy: how do diet, exercise and weight loss drug therapies improve metabolic disease in overweight patients? Expert Rev Cardiovasc Ther 2006 Nov;4(6):871-895.
  19. Canagliflozin, a sodium glucose co-transporter 2 inhibitor, improves model-based indices of beta-cell function in patients with type 2 diabetes. Diabetologia 2014 May;57(5):891-901.
  20. Changes in renal function during acute insulin-induced hypoglycaemia in patients with type 1 diabetes. Diabet Med 1992 Mar;9(2):150-155.
  21. Safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple rising doses of empagliflozin in patients with type 2 diabetes mellitus. Diabetes Ther 2013 Dec;4(2):331-345.
  22. Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes. Diabetes Obes Metab 2013 Sep;15(9):853-862.
  23. Treatment of hypertension and metabolic syndrome: lowering blood pressure is not enough for organ protection, new approach-arterial destiffening. Curr Hypertens Rep 2014 Oct;16(10):479.
  24. The sodium glucose co-transporter 2 inhibitor (SGLT2i) empagliflozin reduces weight and markers of visceral adiposity (VA) in type 2 diabetes (T2D) in short-and intermediate term. Diabetes and Vascular Disease Research. 2016 Mar;13(2):119-126.
  25. The effect of sodium glucose cotransporter 2 inhibition with empagliflozin on microalbuminuria and macroalbuminuria in patients with type 2 diabetes. Diabetologia. 2016 Jun 17.
  26. SGLT-2 inhibitor lowers serum uric acid through alteration of uric acid transport activity in renal tubule by increased glycosuria. Biopharm Drug Dispos 2014 Oct;35(7):391-404.
  27. Changes in lipid profiles of patients with type 2 diabetes mellitus on dapagliflozin therapy. Diabetologia 2013;(Suppl 947):61.
  28. Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice. Eur J Pharmacol 2013 Sep;715(1-3):246-255.
  29. Effect of prophylactic treatment with empagliflozin on cardiac function and diabetes in CRDH rats. Diabetes. 2014; 63(Suppl 1) A273 (1056-P).
  30. Risk of cardiovascular disease and mortality in overweight and obese patients with type 2 diabetes: an observational study in 13,087 patients. Diabetologia 2009 Jan 1;52(1):65-73.
  31. Understanding the inter-relationship between improved glycaemic control, hypoglycaemia and weight change within a long-term economic model. Diabetes Obes Metab 2010 May 1;12(5): 431-436.
  32. Glucose-lowering drugs or strategies and cardiovascular outcomes in patients with or at risk for type 2 diabetes: a meta-analysis of randomised controlled trials. Lancet Diabetes Endocrinol 2015 May 31;3(5):356-366.
  33. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Eng J Med 2015 Nov 26;373(22):2117-2128.
  34. Vulvovaginitis and balanitis in patients with diabetes treated with dapagliflozin. J Diabetes Complications 2013 Sep-Oct;27(5):479-484.
  35. Management of hyperglycemia in type 2 diabetes, 2015:a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2015 Jan;38(1):140-149.
  36. Genital mycotic infections with canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus: a pooled analysis of clinical studies. Curr Med Res Opin 2014 Jun;30(6):1109-1119.
  37. Euglycemic diabetic ketoacidosis: a predictable, detectable, and preventable safety concern with SGLT2 inhibitors. Diabetes Care 2015 Sep;38(9):1638-1642.
  38. AACE/ACE comprehensive diabetes management algorithm 2015. Endocr Pract 2015 Apr;21(4):438-447.
  39. RSSDI clinical practice recommendations for management of type 2 diabetes mellitus, 2015. Int J Diabetes Dev Ctries 2015 Oct;35(Suppl 1): S1-S71.
  40. Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus of different ethnicity. Ethn Dis 2016 Apr 21;26(2):221-228.
  41. Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus from India. Indian journal of endocrinology and metabolism. 2016 May;20(3):372.
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.